Alkermes (ALKS) Share-based Compensation (2010 - 2026)
Alkermes (ALKS) reported Share-based Compensation of $36.3 million for Q1 2026, up 59.27% year-over-year from $22.8 million in Q1 2025, and up 38.27% quarter-over-quarter from $26.3 million in Q4 2025.
Alkermes (ALKS) Share-based Compensation (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Share-based Compensation data on file, last reported at $36.3 million in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $36.3 million, up 59.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $75.6 million (up 35.57% YoY), and the FY2025 annual result was $98.7 million, up 2.15% from the prior year.
- Share-based Compensation rose to $36.3 million in Q1 2026 per ALKS's latest filing, from $26.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $36.3 million in Q1 2026 and troughed at $6.0 million in Q2 2024.
- A 5-year average of $21.1 million and a median of $23.4 million in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2026: Share-based Compensation sank 78.88% in 2024, then surged 59.27% in 2026.
- A 5-year view of Share-based Compensation shows it stood at $26.5 million in 2022, then slipped by 2.42% to $25.8 million in 2023, then declined by 19.72% to $20.7 million in 2024, then grew by 26.64% to $26.3 million in 2025, then surged by 38.27% to $36.3 million in 2026.
- Business Quant data shows ALKS's Share-based Compensation at $36.3 million in Q1 2026, $26.3 million in Q4 2025, and $6.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 43.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 25.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 33.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | -395,114.54 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 57.20 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 21.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 36.33 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 16.04 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 36.86 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 9.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.33 Mn |
| Mar 31, 2026 | 36.33 Mn |
| Dec 31, 2025 | 26.28 Mn |
| Dec 31, 2025 | 26.28 Mn |
| Sep 30, 2025 | 6.44 Mn |
| Sep 30, 2025 | 6.44 Mn |
| Jun 30, 2025 | 6.51 Mn |
| Jun 30, 2025 | 6.51 Mn |
| Mar 31, 2025 | 22.81 Mn |
| Mar 31, 2025 | 22.81 Mn |
| Dec 31, 2024 | 20.75 Mn |
| Dec 31, 2024 | 20.75 Mn |
| Sep 30, 2024 | 6.15 Mn |
| Sep 30, 2024 | 6.15 Mn |
| Jun 30, 2024 | 6.02 Mn |
| Jun 30, 2024 | 6.02 Mn |
| Mar 31, 2024 | 32.76 Mn |
| Mar 31, 2024 | 32.76 Mn |
| Dec 31, 2023 | 25.84 Mn |
| Dec 31, 2023 | 25.84 Mn |